The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Effect of VKORC1 Haplotypes on Transcriptional Regulation and Warfarin Dose
Open accessAbstract
BACKGROUND: The management of warfarin therapy is complicated by a wide variation among patients in drug response. Variants in the gene encoding vitamin K epoxide reductase complex 1 (VKORC1) may affect the response to warfarin. METHODS: We conducted a retrospective study of European-American patients receiving long-term warfarin maintenance therapy. Multiple linear-regression analysis was used to determine the effect of VKORC1 haplotypes on the warfarin dose. We determined VKORC1 haplotype frequencies in African-American, European-American, and Asian-American populations and VKORC1 messenger RNA (mRNA) expression in human liver samples. RESULTS: We identified 10 common noncoding VKORC1 single-nucleotide polymorphisms and inferred five major haplotypes. We identified a low-dose haplotype group (A) and a high-dose haplotype group (B). The mean (+/-SE) maintenance dose of warfarin differed significantly among the three haplotype group combinations, at 2.7+/-0.2 mg per day for A/A, 4.9+/-0.2 mg per day for A/B, and 6.2+/-0.3 mg per day for B/B (P<0.001). VKORC1 haplotype groups A and B explained approximately 25 percent of the variance in dose. Asian Americans had a higher proportion of group A haplotypes and African Americans a higher proportion of group B haplotypes. VKORC1 mRNA levels varied according to the haplotype combination. CONCLUSIONS: VKORC1 haplotypes can be used to stratify patients into low-, intermediate-, and high-dose warfarin groups and may explain differences in dose requirements among patients of different ancestries. The molecular mechanism of this warfarin dose response appears to be regulated at the transcriptional level.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Comparison of Bayesian Methods for Haplotype Reconstruction from Population Genotype Data
Stephens, M., & Donnelly, P. (2003) · The American Journal of Human Genetics · doi:10.1086/379378 · Cited by 3,513
A comprehensive review of genetic association studies
Hirschhorn, J. N., Lohmueller, K., Byrne, E., & Hirschhorn, K. (2002) · Genetics in Medicine · doi:10.1097/00125817-200203000-00002 · Cited by 1,674
The Pharmacology and Management of the Vitamin K Antagonists
Ansell, J., Hirsh, J., Poller, L., Bussey, H., Jacobson, A., & Hylek, E. (2004) · Chest · doi:10.1378/chest.126.3_suppl.204s · Cited by 1,528
Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2
Rost, S., Fregin, A., Ivaskevicius, V., Conzelmann, E., Hörtnagel, K., Pelz, H.-J., Lappegard, K., Seifried, E., Scharrer, I., Tuddenham, E. G. D., et al. (2004) · Nature · doi:10.1038/nature02214 · Cited by 1,134
Higashi, M. K. (2002) · JAMA · doi:10.1001/jama.287.13.1690 · Cited by 1,048
Drysdale, C. M., McGraw, D. W., Stack, C. B., Stephens, J. C., Judson, R. S., Nandabalan, K., Arnold, K., Ruano, G., & Liggett, S. B. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.19.10483 · Cited by 964
Paine, M. F., Khalighi, M., Fisher, J. M., Shen, D. D., Kunze, K. L., Marsh, C. L., Perkins, J. D., & Thummel, K. E. (1997) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37149-6 · Cited by 789
Self-citationIdentification of the gene for vitamin K epoxide reductase
Li, T., Chang, C.-Y., Jin, D.-Y., Lin, P.-J., Khvorova, A., & Stafford, D. W. (2004) · Nature · doi:10.1038/nature02254 · Cited by 707
D'Andrea, G., D'Ambrosio, R. L., Di Perna, P., Chetta, M., Santacroce, R., Brancaccio, V., Grandone, E., & Margaglione, M. (2005) · Blood · doi:10.1182/blood-2004-06-2111 · Cited by 699
Rettie, A. E., Korzekwa, K. R., Kunze, K. L., Lawrence, R. F., Eddy, A. C., Aoyama, T., Gelboin, H. V., Gonzalez, F. J., & Trager, W. F. (1992) · Chemical Research in Toxicology · doi:10.1021/tx00025a009 · Cited by 601
Self-citation
Cited by
Zanger, U. M., & Schwab, M. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.12.007 · Cited by 4,169
Pharmacology and Management of the Vitamin K Antagonists
Ansell, J., Hirsh, J., Hylek, E., Jacobson, A., Crowther, M., & Palareti, G. (2008) · Chest · doi:10.1378/chest.08-0670 · Cited by 2,118
Estimation of the Warfarin Dose with Clinical and Pharmacogenetic Data
(2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809329 · Cited by 1,577
The Pharmacology and Management of the Vitamin K Antagonists
Ansell, J., Hirsh, J., Poller, L., Bussey, H., Jacobson, A., & Hylek, E. (2004) · Chest · doi:10.1378/chest.126.3_suppl.204s · Cited by 1,528
Ageno, W., Gallus, A. S., Wittkowsky, A., Crowther, M., Hylek, E. M., & Palareti, G. (2012) · Chest · doi:10.1378/chest.11-2292 · Cited by 1,503
Pharmacogenetics: From Bench to Byte— An Update of Guidelines
Swen, J. J., Nijenhuis, M., de Boer, A., Grandia, L., Maitland-van der Zee, A. H., Mulder, H., Rongen, G. A. P. J. M., van Schaik, R. H. N., Schalekamp, T., Touw, D. J., et al. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.34 · Cited by 1,018
Mapping the Genetic Architecture of Gene Expression in Human Liver
Schadt, E. E., Molony, C., Chudin, E., Hao, K., Yang, X., Lum, P. Y., Kasarskis, A., Zhang, B., Wang, S., Suver, C., et al. (2008) · PLoS Biology · doi:10.1371/journal.pbio.0060107 · Cited by 921
Charting a course for genomic medicine from base pairs to bedside
National Human Genome Research Institute, Green, E. D., & Guyer, M. S. (2011) · Nature · doi:10.1038/nature09764 · Cited by 902
Use of Pharmacogenetic and Clinical Factors to Predict the Therapeutic Dose of Warfarin
Gage, B., Eby, C., Johnson, J., Deych, E., Rieder, M., Ridker, P., Milligan, P., Grice, G., Lenzini, P., Rettie, A., et al. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.10 · Cited by 847
Self-citationAnderson, J. L., Horne, B. D., Stevens, S. M., Grove, A. S., Barton, S., Nicholas, Z. P., Kahn, S. F. S., May, H. T., Samuelson, K. M., Muhlestein, J. B., et al. (2007) · Circulation · doi:10.1161/circulationaha.107.737312 · Cited by 727
Pharmacogenomics and Individualized Drug Therapy
Eichelbaum, M., Ingelman-Sundberg, M., & Evans, W. E. (2006) · Annual Review of Medicine · doi:10.1146/annurev.med.56.082103.104724 · Cited by 720
Johnson, J., Caudle, K., Gong, L., Whirl‐Carrillo, M., Stein, C., Scott, S., Lee, M., Gage, B., Kimmel, S., Perera, M., et al. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.668 · Cited by 716
Self-citationShen, A. Y.-J., Yao, J. F., Brar, S. S., Jorgensen, M. B., & Chen, W. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.01.098 · Cited by 656
Johnson, J. A., Gong, L., Whirl-Carrillo, M., Gage, B. F., Scott, S. A., Stein, C. M., Anderson, J. L., Kimmel, S. E., Lee, M. T. M., Pirmohamed, M., et al. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.185 · Cited by 647
Self-citationTakeuchi, F., McGinnis, R., Bourgeois, S., Barnes, C., Eriksson, N., Soranzo, N., Whittaker, P., Ranganath, V., Kumanduri, V., McLaren, W., et al. (2009) · PLoS Genetics · doi:10.1371/journal.pgen.1000433 · Cited by 632
Wang, L., McLeod, H. L., & Weinshilboum, R. M. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1010600 · Cited by 613
Self-citationGenetic Determinants of Response to Warfarin during Initial Anticoagulation
Schwarz, U. I., Ritchie, M. D., Bradford, Y., Li, C., Dudek, S. M., Frye-Anderson, A., Kim, R. B., Roden, D. M., & Stein, C. M. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708078 · Cited by 577
The largest prospective warfarin-treated cohort supports genetic forecasting
Wadelius, M., Chen, L. Y., Lindh, J. D., Eriksson, N., Ghori, M. J. R., Bumpstead, S., Holm, L., McGinnis, R., Rane, A., & Deloukas, P. (2009) · Blood · doi:10.1182/blood-2008-04-149070 · Cited by 550
CYP4F2 genetic variant alters required warfarin dose
Caldwell, M. D., Awad, T., Johnson, J. A., Gage, B. F., Falkowski, M., Gardina, P., Hubbard, J., Turpaz, Y., Langaee, T. Y., Eby, C., et al. (2008) · Blood · doi:10.1182/blood-2007-11-122010 · Cited by 521
Self-citationA genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose
Cooper, G. M., Johnson, J. A., Langaee, T. Y., Feng, H., Stanaway, I. B., Schwarz, U. I., Ritchie, M. D., Stein, C. M., Roden, D. M., Smith, J. D., et al. (2008) · Blood · doi:10.1182/blood-2008-01-134247 · Cited by 481
Self-citationPharmacogenetics, Pharmacogenomics, and Individualized Medicine
Ma, Q., & Lu, A. Y. H. (2011) · Pharmacological Reviews · doi:10.1124/pr.110.003533 · Cited by 464
Roden, D. M., McLeod, H. L., Relling, M. V., Williams, M. S., Mensah, G. A., Peterson, J. F., & Van Driest, S. L. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31276-0 · Cited by 427
Self-citationEvaluating coverage of genome-wide association studies
Barrett, J. C., & Cardon, L. R. (2006) · Nature Genetics · doi:10.1038/ng1801 · Cited by 415
Pharmacogenetics, Drug-Metabolizing Enzymes, and Clinical Practice
Gardiner, S. J., & Begg, E. J. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.6 · Cited by 406
Dichgans, M. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70028-5 · Cited by 397
Age-Related Pharmacokinetic and Pharmacodynamic Changes and Related Risk of Adverse Drug Reactions
Corsonello, A., Pedone, C., & Incalzi, R. (2010) · Current Medicinal Chemistry · doi:10.2174/092986710790416326 · Cited by 391
Association of warfarin dose with genes involved in its action and metabolism
Wadelius, M., Chen, L. Y., Eriksson, N., Bumpstead, S., Ghori, J., Wadelius, C., Bentley, D., McGinnis, R., & Deloukas, P. (2007) · Human Genetics · doi:10.1007/s00439-006-0260-8 · Cited by 390
Takahashi, H., Wilkinson, G. R., Nutescu, E. A., Morita, T., Ritchie, M. D., Scordo, M. G., Pengo, V., Barban, M., Padrini, R., Ieiri, I., et al. (2006) · Pharmacogenetics and Genomics · doi:10.1097/01.fpc.0000184955.08453.a8 · Cited by 376
Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups
Limdi, N. A., Wadelius, M., Cavallari, L., Eriksson, N., Crawford, D. C., Lee, M.-T. M., Chen, C.-H., Motsinger-Reif, A., Sagreiya, H., Liu, N., et al. (2010) · Blood · doi:10.1182/blood-2009-12-255992 · Cited by 370
Self-citationCaraco, Y., Blotnick, S., & Muszkat, M. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100316 · Cited by 360
Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research
Arranz, M. J., & de Leon, J. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4002009 · Cited by 351
Warfarin Genotyping Reduces Hospitalization Rates
Epstein, R. S., Moyer, T. P., Aubert, R. E., O'Kane, D. J., Xia, F., Verbrugge, R. R., Gage, B. F., & Teagarden, J. R. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.03.009 · Cited by 336
Self-citationPharmacogenetics of warfarin: current status and future challenges
Wadelius, M., & Pirmohamed, M. (2007) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500417 · Cited by 330
McDonald, M. G., Rieder, M. J., Nakano, M., Hsia, C. K., & Rettie, A. E. (2009) · Molecular Pharmacology · doi:10.1124/mol.109.054833 · Cited by 320
Self-citationEvolution in Health and Disease
(2007) · doi:10.1093/acprof:oso/9780199207466.001.0001 · Cited by 320
Precision Medicine: Disease Subtyping and Tailored Treatment
Wang, R. C., & Wang, Z. (2023) · Cancers · doi:10.3390/cancers15153837 · Cited by 315
Orho-Melander, M., Melander, O., Guiducci, C., Perez-Martinez, P., Corella, D., Roos, C., Tewhey, R., Rieder, M. J., Hall, J., Abecasis, G., et al. (2008) · Diabetes · doi:10.2337/db08-0516 · Cited by 301
Self-citationUse and Effectiveness of Warfarin in Medicare Beneficiaries With Atrial Fibrillation
Birman-Deych, E., Radford, M. J., Nilasena, D. S., & Gage, B. F. (2006) · Stroke · doi:10.1161/01.str.0000208294.46968.a4 · Cited by 301
Self-citationGenomic regions exhibiting positive selection identified from dense genotype data
Carlson, C. S., Thomas, D. J., Eberle, M. A., Swanson, J. E., Livingston, R. J., Rieder, M. J., & Nickerson, D. A. (2005) · Genome Research · doi:10.1101/gr.4326505 · Cited by 298
Self-citationVitamin K Nutrition, Metabolism, and Requirements: Current Concepts and Future Research
Shearer, M. J., Fu, X., & Booth, S. L. (2012) · Advances in Nutrition · doi:10.3945/an.111.001800 · Cited by 296
Kimmel, S. E. (2007) · Archives of Internal Medicine · doi:10.1001/archinte.167.3.229 · Cited by 290
Stroke prevention in atrial fibrillation: An Asian perspective
Wang, K.-L., Lip, G. Y. H., & Chiang, C.-E. (2014) · Thrombosis and Haemostasis · doi:10.1160/th13-11-0948 · Cited by 287
Eckman, M. H., Rosand, J., Greenberg, S. M., & Gage, B. F. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-2-200901200-00005 · Cited by 283
Self-citationPharmacogenomics: Challenges and Opportunities
Roden, D. M., Altman, R. B., Benowitz, N. L., Flockhart, D. A., Giacomini, K. M., Johnson, J. A., Krauss, R. M., McLeod, H. L., Ratain, M. J., Relling, M. V., et al. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-10-200611210-00007 · Cited by 282
Self-citationClarification of Terminology in Medication Errors: Definitions and Classification
Ferner, R. E., & Aronson, J. K. (2006) · Drug Safety · doi:10.2165/00002018-200629110-00001 · Cited by 280
Perera, M. A., Cavallari, L. H., Limdi, N. A., Gamazon, E. R., Konkashbaev, A., Daneshjou, R., Pluzhnikov, A., Crawford, D. C., Wang, J., Liu, N., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60681-9 · Cited by 276
Self-citationAQUILANTE, C., LANGAEE, T., LOPEZ, L., YARANDI, H., TROMBERG, J., MOHUCZY, D., GASTON, K., WADDELL, C., CHIRICO, M., & JOHNSON, J. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.11.011 · Cited by 266
Geisen, C., Watzka, M., Sittinger, K., Steffens, M., Daugela, L., Seifried, E., Müller, C. R., Wienker, T. F., & Oldenburg, J. (2005) · Thrombosis and Haemostasis · doi:10.1160/th05-04-0290 · Cited by 259
Bioinformatics challenges for personalized medicine
Fernald, G. H., Capriotti, E., Daneshjou, R., Karczewski, K. J., & Altman, R. B. (2011) · Bioinformatics · doi:10.1093/bioinformatics/btr295 · Cited by 258
The Current State of Knowledge on Age, Sex, and Their Interactions on Clinical Pharmacology
Schwartz, J. B. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100226 · Cited by 256
Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues
Gage, B. F., & Lesko, L. J. (2008) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-007-0104-y · Cited by 254
Self-citationMeyer, U. A., Zanger, U. M., & Schwab, M. (2013) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010510-100502 · Cited by 157
Learning one’s genetic risk changes physiology independent of actual genetic risk
Turnwald, B. P., Goyer, J. P., Boles, D. Z., Silder, A., Delp, S. L., & Crum, A. J. (2018) · Nature Human Behaviour · doi:10.1038/s41562-018-0483-4 · Cited by 142
A policy model to evaluate the benefits, risks and costs of warfarin pharmacogenomic testing
Meckley, L. M., Gudgeon, J. M., Anderson, J. L., Williams, M. S., & Veenstra, D. L. (2010) · PharmacoEconomics · doi:10.2165/11318240-000000000-00000 · Cited by 97
Self-citationCardiovascular pharmacogenomics and individualized drug therapy
Pereira, N. L., & Weinshilboum, R. M. (2009) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2009.154 · Cited by 72
Metadata
- Authors
- Rieder, M. J., Reiner, A. P., Gage, B. F., Nickerson, D. A., Eby, C. S., McLeod, H. L., Blough, D. K., Thummel, K. E., Veenstra, D. L., & Rettie, A. E.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2005-06-02
- Volume
- 352
- Issue
- 22
- Pages
- 2285-2293
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2043674997
- Cited by
- 1,399
- References
- 18
- FWCI
- 98.05
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.